STOCK TITAN
  1. Home
  2. News
  3. CUE

Cue Biopharma Inc - CUE STOCK NEWS

Welcome to our dedicated news page for Cue Biopharma (Ticker: CUE), a resource for investors and traders seeking the latest updates and insights on Cue Biopharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cue Biopharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cue Biopharma's position in the market.

News
Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights
Rhea-AI Summary
Cue Biopharma, Inc. reported positive data from Phase 1 trials of CUE-101 and CUE-102 for cancer treatment. The company completed enrollment for CUE-101 trials and received FDA guidance for potential registrational trials. Financially, collaboration revenue increased significantly in 2023, with research and development expenses slightly decreasing. However, the company's cash reserves declined, with operations expected to be funded until Q1 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.86%
Tags
earnings
-
News
Cue Biopharma to Host Business Update Call and Webcast
Rhea-AI Summary
Cue Biopharma, Inc. (CUE) will host a conference call and webcast to provide a business update on April 8, 2024. The update will focus on advancing its clinical oncology programs, CUE-101 and CUE-102, as well as its preclinical autoimmune program CUE-401. The company will also discuss additional autoimmune pipeline developments and business updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.21%
Tags
conferences
-
News
Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium
Rhea-AI Summary
Cue Biopharma, Inc. (Nasdaq: CUE) announces the presentation of CUE-101 at the 2024 Multi-disciplinary Head and Neck Cancers Symposium. The data highlights include an overall response rate of 47% in first-line patients and a median overall survival of 20.8 months in second-line patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.12%
Tags
none
News
Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
Cue Biopharma, Inc. (Nasdaq: CUE) will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, providing a corporate update on its lead clinical programs, CUE-101 and CUE-102, as well as its lead preclinical autoimmune program partnered with Ono Pharmaceutical. The presentation will also cover market opportunities, competitive positioning, and key forecasted value-driving 2024 milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.46%
Tags
conferences
-
News
Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit
Rhea-AI Summary
Cue Biopharma, Inc. (CUE) will take part in a fireside chat at the JMP Securities Hematology and Oncology Summit on December 5-6, 2023. The company will discuss recent data highlights from its lead clinical programs, CUE-101 and CUE-102, as well as market opportunities, competitive positioning, and anticipated milestones for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
conferences
-
News
Cue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights
Rhea-AI Summary
Cue Biopharma, Inc. (CUE) provided a business and financial update for the third quarter of 2023, presenting positive data from ongoing Phase 1 trials of CUE-101 and CUE-102 at the Society for Immunotherapy of Cancer’s 38th Anniversary Annual Meeting. Financially, the company reported collaboration revenue of approximately $2.1 million for the three months ended September 30, 2023, and $3.7 million for the nine months ended September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.33%
Tags
earnings
News
Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November
Rhea-AI Summary
Cue Biopharma, Inc. (CUE) will participate in three investor conferences this November to provide a corporate overview, including recent data highlights from its lead clinical programs, CUE-101 and CUE-102, representative of the IL-2-based CUE-100 series of selective T cell engagers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News
Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023
Rhea-AI Summary
Cue Biopharma announced positive data from Phase 1 trials of its T cell engagers, CUE-101 and CUE-102, for head and neck cancer and WT1-positive cancers. CUE-101 showed an overall response rate (ORR) of 47% and disease control rate (DCR) of 65% in first-line recurrent/metastatic HNSCC patients. CUE-101 also demonstrated a median overall survival (mOS) of 20.8 months in second-line and beyond patients, compared to historic survival rates of approximately eight months. CUE-102 showed promising results with no dose-limiting toxicities observed and a disease control rate (DCR) of 75%-80% at different doses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.36%
Tags
clinical trial
-
News
Cue Biopharma to Host Business Update Call and Webcast
Rhea-AI Summary
Cue Biopharma, Inc. will host a conference call and webcast on November 9, 2023, to provide a business and clinical update. The company will discuss the progress of its Phase 1 trials for CUE-101 and CUE-102, its IL-2 based biologics for the treatment of head and neck cancer and WT1 expressing cancers. Additional clinical, pipeline, and business updates will also be addressed. Positive data from the clinical programs will be presented at the SITC 2023 Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.9%
Tags
conferences
News
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
Rhea-AI Summary
Cue Biopharma to present two poster presentations at SITC 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.39%
Tags
conferences
Stock CUE logo
Cue Biopharma Inc

Nasdaq:CUE

CUE Rankings

#4452 Ranked by Market Cap
#3994 Ranked by Stock Gains
N/A Ranked by Dividends

CUE Stock Data

85.13M
45.38M
2.97%
32.9%
8.64%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Cambridge

About CUE

cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci